Drugs for Pyoderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 46)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Infliximab |
Approved |
Phase 4,Not Applicable |
|
170277-31-3 |
|
Synonyms:
Ig gamma-1 chain C region
Infliximab (genetical recombination)
Infliximab-abda
|
Infliximab-dyyb
Infliximab-qbtx
Remicade
|
|
2 |
|
Anti-Infective Agents |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
3 |
|
Anti-Bacterial Agents |
|
Phase 4,Phase 3 |
|
|
|
4 |
|
Dermatologic Agents |
|
Phase 4,Phase 2,Not Applicable |
|
|
|
5 |
|
Gastrointestinal Agents |
|
Phase 4,Not Applicable |
|
|
|
6 |
|
Antirheumatic Agents |
|
Phase 4,Phase 3,Phase 2,Not Applicable |
|
|
|
7 |
|
Minocycline |
Approved, Investigational |
Phase 3 |
|
10118-90-8 |
5281021
|
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-dimethylamino-6-Demethyl-6-deoxytetracycline
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
Alti-Minocycline
Apo-Minocycline
Arestin
Bio-0062
Borymycin
BRN 3077644
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
Dynacin
Gen-Minocycline
HMS2090D03
HSDB 3130
Klinomycin
Lactoferrin B & Minocycline
|
Lactoferrin H & Minocycline
LMPK07000002
LS-93850
MINO
Minociclina
Minociclina [INN-Spanish]
minociclinum
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
minocycline
Minocycline (USAN/INN)
Minocycline [USAN:BAN:INN]
Minocycline HCl
Minocycline Monohydrochloride
Minocyclinum
Minocyclinum [INN-Latin]
Minocyn
Minomycin
MIY
NCGC00178854-01
nchembio.559-comp1
Novo-Minocycline
NSC 141993
NSC141993
Solodyn
UNII-FYY3R43WGO
Vectrin
Vectrin (Hydrochloride)
|
|
8 |
|
Adalimumab |
Approved |
Phase 2, Phase 3,Phase 3 |
|
331731-18-1 |
16219006
|
Synonyms:
331731-18-1
Adalimumab
Adalimumab (genetical recombination)
Adalimumab (genetical recombination) (JAN)
Adalimumab (USAN/INN)
adalimumab-adaz
adalimumab-adbm
|
adalimumab-atto
D02597
Humira
Humira (TN)
Humira Pen
Ig gamma-1 chain C region
|
|
9 |
|
Ivermectin |
Approved, Investigational, Vet_approved |
Phase 3,Phase 2 |
|
70288-86-7 |
6474909
|
Synonyms:
(2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-20,20b-dihydroxy-5',6,8,19-tetramethyl-6'-[(1S)-1-methylpropyl]-17-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside
71827-03-7
AB00513813
AC1MJ4GR
AC1N7O27
BPBio1_000322
BRD-K24652731-001-02-7
BSPBio_000292
CHEMBL341047
CID11957587
CID4330618
CID6321424
CID6419971
CID6427057
EU-0100693
FT-0082656
HMS1568O14
HMS2089M09
I 8898
I8898_SIGMA
|
Ivermectin
IVERMECTIN
Ivermectina
Ivermectine
Ivermectinum
Lopac0_000693
MK-933
MLS001333247
MLS001333248
MLS002153248
MolPort-006-394-715
NCGC00094047-01
NCGC00094047-02
NCGC00094047-03
Prestwick_516
Prestwick2_000156
Prestwick3_000156
S1351_Selleck
SMR000857211
|
|
10 |
|
Azathioprine |
Approved |
Phase 3 |
|
446-86-6 |
2265
|
Synonyms:
[Methyl(nitroimidazolyl)mercaptopurine]
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC1L1DAL
AC1Q3Z1F
AC-4230
AI3-50290
AI-981/34845012
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
azathioprine
Azathioprine (JP15/USP/INN)
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprine Sodium
Azathioprine sodium salt
Azathioprine sulfate
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
azatiopr in
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57322
BW 57-322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
Ccucol
CHEBI:2948
CHEMBL1542
ChemDiv1_002659
CID2265
cMAP_000046
CPD000427366
Cytostatics
D00238
DB00993
DivK1c_000586
EINECS 207-175-4
|
EU-0100027
FT-0083532
HMS1568C10
HMS1920E17
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (tn)
Imuran (TN)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
Lopac0_000027
Lopac-A-4638
LS-123
Methylnitroimidazolylmercaptopurine
MLS001049307
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC39084
NSC-39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick_41
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
Sodium, azathioprine
SPBio_000255
SPBio_001987
Spectrum_000064
SPECTRUM1500133
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
STK831906
STOCK1S-20293
STOCK1S-27186
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
|
|
11 |
|
Prednisone |
Approved, Vet_approved |
Phase 3 |
|
53-03-2 |
5865
|
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17a,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17α,21-diol-3,11,20-trione
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
Acis brand OF prednisone
ACon0_000082
ACon1_000297
Adasone
AI3-52939
Ancortone
apo-Prednisone
Apo-prednisone
Apo-Prednisone
Apotex brand OF prednisone
Aventis brand OF prednisone
Betapar
Bicortone
Bio-0649
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
C07370
C21H26O5
Cartancyl
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
CPD001227202
Cutason
Dacorten
Dacortin
DB00635
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
delta cortelan
Delta Cortelan
Delta E
Delta E.
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
Delta-cortelan
Delta-Cortelan
Deltacortene
delta-Cortisone
Deltacortisone
Delta-cortisone
delta-Cortone
Deltacortone
Delta-cortone
Delta-dome
Delta-Dome
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Diadreson
Di-Adreson
Diba brand OF prednisone
Econosone
EINECS 200-160-3
Encorton
Encortone
Enkortolon
Enkorton
Fawns and mcallan brand OF prednisone
Fernisone
Ferring brand OF prednisone
Fiasone
GALENpharma brand OF prednisone
Halsey drug brand OF prednisone
Hexal brand OF prednisone
HMS1568O15
HMS2090J13
|
Hoechst brand OF prednisone
Hostacortin
HSDB 3168
ICN brand OF prednisone
Incocortyl
In-Sone
Juvason
Kortancyl
Lichtenstein brand OF prednisone
Liquid pred
Liquid Pred
Lisacort
LMST02030180
Lodotra
LS-1325
MEGxm0_000443
Me-Korti
Merck brand OF prednisone
Merz brand OF prednisone
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
Mibe brand OF prednisone
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI60_000008
NCI-C04897
Nisona
Nizon
Novoprednisone
NSC 10023
NSC10023
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Pharmacia brand OF prednisone
PRD
Precort
Predeltin
Predni tablinen
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Predniment
Prednison
Prednison acsis
Prednison galen
Prednison hexal
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone [INN:BAN]
Prednisone Intensol
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick_405
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
Schering-plough brand OF prednisone
Seatrace brand OF prednisone
Servisone
SK-Prednisone
SMR000718760
SMR001227202
Solvay brand OF prednisone
Sone
SPBio_002214
Sterapred
Supercortil
Trommsdorff brand OF prednisone
U 6020
Ultracorten
Ultracortene
UNII-VB0R961HZT
Winpred
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Wojtab
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
ZINC03875357
|
|
12 |
|
Mesalamine |
|
Phase 3,Phase 2 |
|
89-57-6 |
|
13 |
|
Analgesics, Non-Narcotic |
|
Phase 3 |
|
|
|
14 |
|
Peripheral Nervous System Agents |
|
Phase 3 |
|
|
|
15 |
|
Anti-Inflammatory Agents |
|
Phase 3,Phase 2 |
|
|
|
16 |
|
Analgesics |
|
Phase 3 |
|
|
|
17 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 3 |
|
|
|
18 |
|
Antiparasitic Agents |
|
Phase 3,Phase 2 |
|
|
|
19 |
|
Aspartic Acid |
|
Phase 3 |
|
|
|
20 |
|
alanine |
|
Phase 3 |
|
|
|
21 |
|
Immunologic Factors |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
22 |
|
Hormone Antagonists |
|
Phase 3 |
|
|
|
23 |
|
Liver Extracts |
|
Phase 3 |
|
|
|
24 |
|
N-Methylaspartate |
|
Phase 3 |
|
|
|
25 |
|
Immunosuppressive Agents |
|
Phase 3,Phase 2 |
|
|
|
26 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
27 |
|
glucocorticoids |
|
Phase 3 |
|
|
|
28 |
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
Phase 3 |
|
|
|
29 |
|
Hormones |
|
Phase 3 |
|
|
|
30 |
|
Antimetabolites, Antineoplastic |
|
Phase 3 |
|
|
|
31 |
|
Antineoplastic Agents, Hormonal |
|
Phase 3 |
|
|
|
32 |
|
Pharmaceutical Solutions |
|
Phase 3,Phase 2 |
|
|
|
33 |
|
Ixekizumab |
Approved, Investigational |
Phase 2 |
|
1143503-69-8 |
|
34 |
|
Tacrolimus |
Approved, Investigational |
Phase 2 |
|
104987-11-3 |
445643
439492
|
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
Advagraf
AKOS005145901
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
Anhydrous, tacrolimus
BCBcMAP01_000194
Bio-0921
Bio2_000470
Bio2_000950
BRD-K35452788-001-02-1
BSPBio_001279
BSPBio-001279
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
Cilag brand OF tacrolimus
CPD000466356
CPD-10016
D08556
DB00864
DivK1c_001040
FK 506
FK5
Fk-506
FK506
FK-506
FR 900506
FR900506
|
FR-900506
FT-0082660
Fujimycin
Fujisawa brand OF tacrolimus
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
Janssen brand OF tacrolimus
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
nchembio.2007.23-comp2
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Prograft
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
tacrolimus
Tacrolimus (anhydrous)
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus anhydrous
tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
|
|
35 |
|
Antibodies, Monoclonal |
|
Phase 2,Phase 1 |
|
|
|
36 |
|
Immunoglobulins |
|
Phase 2,Phase 1 |
|
|
|
37 |
|
Antibodies |
|
Phase 2,Phase 1 |
|
|
|
38 |
|
Calcineurin Inhibitors |
|
Phase 2 |
|
|
|
39 |
|
Amoxicillin |
Approved, Vet_approved |
|
|
26787-78-0 |
33613
|
Synonyms:
(-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid
(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
26787-78-0
33911-69-2
34642-77-8 (mono-hydrochloride salt)
4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D- (8CI)
6-(a-amino-4-hydroxyphenylacetamido)Penicillanic acid
6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid
6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin
6-(D-(-)-P-Hydroxy-alpha-aminobenzyl)penicillin
6-(P-Hydroxy-a-aminophenylacetamido)penicillanate
6-(P-Hydroxy-a-aminophenylacetamido)penicillanic acid
6-(P-Hydroxy-alpha-aminophenylacetamido)penicillanate
6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid
6-(P-Hydroxy-alpha-aminophenylacetamido)penicillanic acid
6-(P-Hydroxy-α-aminophenylacetamido)penicillanate
6-(p-hydroxy-α-aminophenylacetamido)penicillanic acid
6-(P-Hydroxy-α-aminophenylacetamido)penicillanic acid
6-[[amino(4-Hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 9ci
61336-70-7 (TRIHYDRATE)
6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carbonyl
6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
71447-36-4
81030-75-3
a-amino-P-Hydroxybenzylpenicillin
AC-12263
AC1L1PY2
Actimoxi
Almodan
alpha-amino-P-Hydroxybenzylpenicillin
alpha-Amino-p-hydroxybenzylpenicillin
Ambap26787-78-0
AMC
Amix
Amoclen
Amolin
Amopen
Amopenixin
Amoram
Amox
Amox 250 cap 250MG
Amox 500 cap 500MG
Amox S 125 sus 125mg/5ML
Amox S 250 sus 250mg/5ML
Amoxi
Amoxibiotic
Amoxicaps
Amoxicilina
Amoxicilina [INN-Spanish]
amoxicillanyl
amoxicillin
Amoxicillin
Amoxicillin (anhydrous)
Amoxicillin (INN)
Amoxicillin (TN)
Amoxicillin and clavulanate potassium
Amoxicillin anhydrous
Amoxicillin clariana brand
AMOXICILLIN CRYSTALLINE
Amoxicillin monopotassium salt
Amoxicillin monosodium salt
Amoxicillin pediatric
AMOXICILLIN PEDIATRIC
Amoxicillin sodium
Amoxicillin trihydrate
Amoxicillin Trihydrate
Amoxicillin(usan)
Amoxicillin, (r*)-isomer
Amoxicilline
Amoxicilline [INN]
Amoxicilline [INN-French]
Amoxicillinum
Amoxicillinum [INN-Latin]
Amoxid
Amoxiden
Amoxil
Amoxi-mast
Amoxi-Mast
Amoxivet
Amoxycilin
Amoxycillin
Amoxycillin trihydrate
Amoxycillin Trihydrate
Amoxycillin, ban
Amoxymed
AMPC
Amrit
Anemolin
Anhydrous, amoxicillin
apo-Amoxi
Apo-Amoxi
apo-Amoxi cap 250MG
apo-Amoxi cap 500MG
apo-Amoxi PWR for susp 125mg/5ML
apo-Amoxi PWR for susp 250mg/5ML
apo-Amoxi sugar free
Aspenil
AUGMENTIN '125'
AUGMENTIN '200'
AUGMENTIN '250'
AUGMENTIN '400'
AUGMENTIN '500'
AUGMENTIN '875'
AUGMENTIN es-600
AX
Biomox
BLP 1410
BL-P 1410
|
BPBio1_000499
BRD-K55044200-001-03-9
Bristamox
BRL 2333
BRL-2333
BSPBio_000453
C06827
Cemoxin
CHEBI:2676
CHEBI:53712
CHEMBL1082
CID33613
Clamoxyl
Clamoxyl (SKB)
Clamoxyl g.a.
Clamoxyl parenteral
Clariana brand OF amoxicillin
CPD000058707
D-(-)-alpha-amino-P-Hydroxybenzyl penicillin
D-(-)-alpha-amino-P-Hydroxybenzylpenicillin
D-(-)-alpha-Amino-p-hydroxybenzylpenicillin
D-(alpha-amino-P-Hydroxybenzyl)penicillin
D07452
D-2-amino-2-(4-Hydroxyphenyl)acetamidopenicillanic acid
D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid
D-Amoxicillin
DB01060
Delacillin
Dispermox
DisperMox
Efpenix
EINECS 248-003-8
Flemoxin
G.A., clamoxyl
Galenamox
Gen-amoxicillin 250MG
Gen-amoxicillin 500MG
Hiconcil
Histocillin
HMS1569G15
HSDB 3204
Hydroxyampicillin
Ibiamox
Imacillin
Lamoxy
Larotid
LS-149721
Metafarma capsules
Metifarma capsules
MLS000028632
MLS002222248
MolPort-003-981-182
MolPort-005-933-687
Moxacin
Moxal
Moxatag
NCGC00179554-01
Novamoxin cap 250MG
Novamoxin cap 500MG
Novamoxin sus 125mg/5ML
Novamoxin sus 250mg/5ML
NSC 277174
NSC277174
Nu-amoxi cap 250MG
Nu-amoxi cap 500MG
Nu-amoxi sus 125/5ML
Nu-amoxi sus 250mg/5ML
Ospamox
Pamoxicillin
Parenteral, clamoxyl
Penamox
Pfizer brand OF amoxicillin sodium salt
PHL-Amoxicillin
p-Hydroxyampicillin
P-Hydroxyampicillin
Piramox
PMS-Amoxicillin
Polymox
Prestwick_713
Prestwick0_000357
Prestwick1_000357
Prestwick2_000357
Prestwick3_000357
Prevpac
pro Amox PWR for oral susp 125mg/5ML
pro Amox-250 cap 250MG
pro Amox-500 cap 500MG
pro-Amox-250 orl sus 250mg/5ML
R-Hydroxyampicillin
Rimoxallin
Ro 10-8756
Robamox
SAM002264592
Sauracillin
Sawamox PM
SmithKline beecham brand OF amoxicillin sodium salt
SMR000058707
Sodium, amoxicillin
SPBio_002374
Sumox
Tolodina
Trihydrate, amoxicillin
Trimox
Unicillin
Utimox
Vetramox
Wymox
Zimox
α-amino-p-hydroxybenzylpenicillin
α-amino-P-hydroxybenzylpenicillin
|
|
40 |
|
Vedolizumab |
Approved |
|
|
943609-66-3 |
|
41 |
|
Certolizumab pegol |
Approved |
|
|
428863-50-7 |
|
Synonyms:
428863-50-7
CDP870
Certolizumab pegol
Certolizumab pegol (genetical recombination)
|
Certolizumab pegol (genetical recombination) (JAN)
Certolizumab pegol (USAN/INN)
cimzia
D03441
|
|
42 |
|
Ustekinumab |
Approved, Investigational |
|
|
815610-63-0 |
|
Synonyms:
|
43 |
|
Vaccines |
|
|
|
|
|
44 |
|
beta-Lactamase Inhibitors |
|
|
|
|
|
45 |
|
Clavulanic Acids |
|
|
|
|
|
46 |
|
Amoxicillin-Potassium Clavulanate Combination |
|
|
|
|
|
Interventional clinical trials:
(show all 38)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery |
Completed |
NCT00688636
|
Phase 4 |
infliximab;placebo |
2 |
Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460) |
Withdrawn |
NCT00202891
|
Phase 4 |
sisomicin |
3 |
Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study |
Unknown status |
NCT00203697
|
Phase 3 |
minocycline |
4 |
A Comparison of Once a Day Dose Compared to 2 Doses/Day |
Completed |
NCT00505778
|
Phase 3 |
Mesalamine Once-Daily;Mesalamine Twice-Daily |
5 |
A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease |
Completed |
NCT00445432
|
Phase 2, Phase 3 |
|
6 |
A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects |
Completed |
NCT01068158
|
Phase 3 |
0.5% Ivermectin Cream;Placebo control |
7 |
A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation |
Completed |
NCT01066585
|
Phase 3 |
Ivermectin Cream;vehicle control |
8 |
Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease |
Completed |
NCT01235689
|
Phase 3 |
Prednisone;Azathioprine |
9 |
A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan |
Recruiting |
NCT03311464
|
Phase 3 |
adalimumab |
10 |
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum |
Terminated |
NCT02326740
|
Phase 3 |
gevokizumab;Placebo;gevokizumab open-label |
11 |
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum |
Terminated |
NCT02315417
|
Phase 3 |
gevokizumab;Placebo;gevokizumab open-label |
12 |
A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum |
Terminated |
NCT02318914
|
Phase 3 |
gevokizumab |
13 |
Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum |
Completed |
NCT01882504
|
Phase 2 |
gevokizumab |
14 |
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum |
Completed |
NCT01965613
|
Phase 2 |
|
15 |
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum |
Completed |
NCT03137160
|
Phase 2 |
|
16 |
Canakinumab for Pyoderma Gangrenosum |
Completed |
NCT01302795
|
Phase 2 |
Canakinumab |
17 |
Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects |
Completed |
NCT00994422
|
Phase 2 |
Ivermectin cream;vehicle control |
18 |
Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease |
Completed |
NCT01233570
|
Phase 2 |
Tacrolimus |
19 |
Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis |
Completed |
NCT01036022
|
Phase 2 |
GSK1399686 |
20 |
Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum |
Recruiting |
NCT02733094
|
Phase 1, Phase 2 |
Secukinumab |
21 |
Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum |
Terminated |
NCT03072953
|
Phase 2 |
APD334 |
22 |
Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease |
Terminated |
NCT00584740
|
Phase 2 |
AIN457;Placebo |
23 |
Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum |
Withdrawn |
NCT00730717
|
Phase 2 |
Humira;Humira |
24 |
Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum |
Withdrawn |
NCT00690846
|
Phase 2 |
adalimumab |
25 |
Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease |
Completed |
NCT00791557
|
Not Applicable |
Infliximab |
26 |
Prevalence of RHD, Pyoderma and Scabies in Children in Fiji |
Completed |
NCT00284843
|
|
|
27 |
Streptococcal Infections in Fiji - Prevalence of Group A Streptococcal Pyoderma and Scabies in Infants in Fiji |
Completed |
NCT00436891
|
|
|
28 |
Incidence of Group A Strep Pharyngitis in School Children in Fiji |
Completed |
NCT00284882
|
|
|
29 |
Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory |
Completed |
NCT00884728
|
|
|
30 |
Special Drug Use Investigation for CLAVAMOX® (Amoxicillin/Clavulanate) Pediatrics Dry Syrup (Every Indication Excluded Otitis Media) |
Completed |
NCT01406275
|
|
Amoxicillin and clavulanate |
31 |
Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors |
Completed |
NCT00933296
|
|
|
32 |
Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases |
Recruiting |
NCT01952275
|
|
|
33 |
A Real World, Observational Registry of Chronic Wounds and Ulcers |
Recruiting |
NCT02280733
|
|
|
34 |
Entyvio (Vedolizumab) Long Term Safety Study |
Recruiting |
NCT02674308
|
|
Vedolizumab |
35 |
Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease |
Recruiting |
NCT03495973
|
|
Ustekinumab |
36 |
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo |
Active, not recruiting |
NCT02902822
|
Not Applicable |
|
37 |
Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum |
Not yet recruiting |
NCT03636737
|
|
|
38 |
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD) |
Terminated |
NCT01577264
|
|
|
Cochrane evidence based reviews: pyoderma
|